The World Health Organization (WHO) states that 1.7 million new cases of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) were recorded in 2019. Further, the International Agency for Research on Cancer (IARC) estimates that a total of 19,292,789 new cancer cases were registered in 2020. In addition, the International Diabetes Federation (IDF) states that nearly 463 million adults in the 20–79 age bracket were living with diabetes in 2019, and the number is expected to rise to 700 million by 2045.
The increasing prevalence of chronic diseases, such as cancer and diabetes, and communicable diseases, such as HIV/AIDS, will help the blood screening market exhibit a CAGR of 8.1% during 2020–2030, as a blood test is mandatory to diagnose these ailments and the blood needs to be screened before donating it. According to P&S Intelligence, the market generated $2,402.3 million revenue in 2019. Additionally, the ongoing COVID-19 pandemic is also creating an extensive requirement for blood screening products globally.
Besides, the surging number of blood donors is also projected to facilitate the adoption of blood screening products worldwide. As per the WHO, approximately 118.4 million blood donations are collected globally, out of which 40% are collected in high-income countries. The WHO further states that nearly 13,300 blood centers in 169 nations collected a total of 106 million donations in 2018. On average, 1,300 donations in low-income countries, 4,400 donations in lower- and middle-income countries, and 9,300 donations in upper-middle-income countries, and 25,700 donations in high-income countries are recorded in each blood center.
Nucleic acid technology (NAT) and enzyme-linked immunosorbent assay (ELISA)-based reagents and kits are used by blood banks, hospitals, clinics, diagnostic centers and pathology labs, and ambulatory surgical centers (ASCs) to screen blood. In comparison to ELISA-based reagents and kits, NAT-based variants are more sensitive, owing to which they will be adopted in enormous quantities in the coming years. Enzymes and polymerases, standards and controls, probes and primers, labeling and detection reagents, and buffers, nucleotides, and solutions are the different types of NAT-based reagents and kits used by end users to screen blood.
In the recent past, North America dominated the blood screening market due to the high incidence of respiratory and infectious diseases. For instance, the Centers for Disease Control and Prevention (CDC) estimates that nearly 7.0% of children under 18 years of age and around 8.0% of adults aged 18 and over in the U.S. are currently living with asthma. The CDC also states that 7,272 emphysema deaths, 145,735 chronic lower respiratory diseases deaths, and 448 bronchitis deaths were recorded in the U.S. in 2019.
Further, the Asia-Pacific (APAC) region will emerge as a significant user of blood screening products in the foreseeable future. This will be on account of the surging prevalence of cancer and other chronic diseases and the increasing presence of manufacturers of such products in the region. For example, the IARC states that a total of 2,252,981 new cancer cases were recorded in Southeast Asia (SEA) in 2020. It also estimates that 298,445 breast cancer, 190,874 cervix uteri cancer, 170,619 lung cancer, 166,900 lip, oral cavity cancer, and 141,928 colorectum cancer cases were diagnosed in 2020.
Therefore, the rising cases of chronic and infectious diseases and the increasing number of blood donors will augment the usage of blood screening products globally.
